Pleural diffuse mesothelial lesions: A challenge for pathologists
暂无分享,去创建一个
G. Angelico | A. Ieni | G. Tuccari | F. Arena
[1] F. Galateau-Sallé,et al. The differential diagnosis between pleural sarcomatoid mesothelioma and spindle cell/pleomorphic (sarcomatoid) carcinomas of the lung: evidence-based guidelines from the International Mesothelioma Panel and the MESOPATH National Reference Center. , 2017, Human pathology.
[2] J. Vergnon,et al. Histopathologic features predict survival in diffuse pleural malignant mesothelioma on pleural biopsies , 2017, Virchows Archiv.
[3] A. Husain,et al. BAP1 immunohistochemistry has limited prognostic utility as a complement of CDKN2A (p16) fluorescence in situ hybridization in malignant pleural mesothelioma. , 2017, Human pathology.
[4] T. Tsuchida,et al. Diagnostic Utility of Pleural Fluid Cell Block versus Pleural Biopsy Collected by Flex-Rigid Pleuroscopy for Malignant Pleural Disease: A Single Center Retrospective Analysis , 2016, PloS one.
[5] G. Scagliotti,et al. BRCA1‐Associated Protein 1 (BAP1) Immunohistochemical Expression as a Diagnostic Tool in Malignant Pleural Mesothelioma Classification: A Large Retrospective Study , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[6] K. Nabeshima,et al. Use of p16 FISH for differential diagnosis of mesothelioma in smear preparations , 2016, Diagnostic cytopathology.
[7] A. Gown,et al. BAP1 Immunohistochemistry and p16 FISH in the Diagnosis of Sarcomatous and Desmoplastic Mesotheliomas , 2016, The American journal of surgical pathology.
[8] F. Galateau-Sallé,et al. The 2015 World Health Organization Classification of Tumors of the Pleura: Advances since the 2004 Classification. , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[9] A. Husain,et al. Malignant Mesothelioma Diagnosis. , 2015, Archives of pathology & laboratory medicine.
[10] C. Bedrossian. An update on pleuro‐pulmonary cytopathology: Part i: Cytological diagnosis of mesothelioma and molecular cytology of lung cancer with an historical perspective , 2015, Diagnostic cytopathology.
[11] A. Fassina,et al. Guidelines for the cytopathologic diagnosis of epithelioid and mixed‐type malignant mesothelioma: Complementary Statement from the International Mesothelioma Interest Group, Also Endorsed by the International Academy of Cytology and the Papanicolaou Society of Cytopathology , 2015, Diagnostic cytopathology.
[12] V. Ascoli. Pathologic diagnosis of malignant mesothelioma: chronological prospect and advent of recommendations and guidelines. , 2015, Annali dell'Istituto superiore di sanita.
[13] A. Fassina,et al. Guidelines for the Cytopathologic Diagnosis of Epithelioid and Mixed-Type Malignant Mesothelioma , 2015, Acta Cytologica.
[14] D. Henderson,et al. Challenges and controversies in the diagnosis of malignant mesothelioma: Part 2. Malignant mesothelioma subtypes, pleural synovial sarcoma, molecular and prognostic aspects of mesothelioma, BAP1, aquaporin-1 and microRNA , 2013, Journal of Clinical Pathology.
[15] D. Henderson,et al. Challenges and controversies in the diagnosis of mesothelioma: Part 1. Cytology-only diagnosis, biopsies, immunohistochemistry, discrimination between mesothelioma and reactive mesothelial hyperplasia, and biomarkers , 2013, Journal of Clinical Pathology.
[16] V Torri,et al. Malignant Pleural Mesothelioma : State of the art and recommendations , 2016 .
[17] A. Gown,et al. Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group. , 2013, Archives of pathology & laboratory medicine.
[18] P. Betta,et al. Immunohistochemistry and molecular diagnostics of pleural malignant mesothelioma. , 2012, Archives of pathology & laboratory medicine.
[19] D. Henderson,et al. Molecular biomarkers in malignant mesothelioma: state of the art , 2011, Pathology.
[20] F. Demirağ,et al. Benign and Malignant Mesothelial Proliferation. , 2010, Surgical pathology clinics.
[21] A. Gown,et al. Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group. , 2009, Archives of pathology & laboratory medicine.
[22] B. Addis,et al. Problems in mesothelioma diagnosis , 2009, Histopathology.
[23] S. Suster,et al. Applications and Limitations of Immunohistochemistry in the Diagnosis of Malignant Mesothelioma , 2006, Advances in anatomic pathology.
[24] J. Silverman,et al. The Diagnosis of Malignancy in Effusion Cytology: A Pattern Recognition Approach , 2006, Advances in anatomic pathology.
[25] Immunohistochemical Diagnostic Approach in Neoplastic Pathology of Mesothelium , 2018 .
[26] G. Alí,et al. The pathological and molecular diagnosis of malignant pleural mesothelioma: a literature review. , 2018, Journal of thoracic disease.
[27] G. Alí,et al. Molecular markers and new diagnostic methods to differentiate malignant from benign mesothelial pleural proliferations: a literature review. , 2018, Journal of thoracic disease.
[28] A. Gown,et al. Guidelines for Pathologic Diagnosis of Malignant Mesothelioma 2017 Update of the Consensus Statement From the International Mesothelioma Interest Group. , 2018, Archives of pathology & laboratory medicine.
[29] S. Monaco,et al. Recent Advances in the Diagnosis of Malignant Mesothelioma: Focus on Approach in Challenging Cases and in Limited Tissue and Cytologic Samples , 2018, Advances in anatomic pathology.
[30] A. Gown,et al. Guidelines for Pathologic Diagnosis of Malignant Mesothelioma , 2017 .
[31] N. Maskell,et al. Biopsy techniques for the diagnosis of mesothelioma. , 2011, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.
[32] Markus Voelter,et al. State of the Art , 1997, Pediatric Research.